Erik Lundgren
CEO & DirectorMr. Erik Lundgren is Chief Executive Officer of Immunic, Inc. from June 1, 2026 and also serves as Director from July 5, 2026. Mr. Lundgren served as Senior Vice President, Commercial Portfolio Organization at Genentech, Inc., a member of the Roche Group, from May 2024 to May 2026, where he led and oversaw the commercial strategy across all therapeutic areas of the company's portfolio. Mr. Lundgren has nearly two decades of biopharmaceutical experience spanning commercial strategy, product launches, global portfolio leadership, marketing and general management, with particular expertise in multiple sclerosis. He also held commercial leadership roles supporting the launches of oncology medicines, including Kadcyla (ado-trastuzumab emtansine) and Zelboraf (vemurafenib) and led various sales teams within Genentech's oncology franchise. Mr. Lundgren was the General Manager of Roche s.r.o. from April 2021 to May 2024. Mr. Lundgren was the Lifecycle Leader for Huntington’s disease at Roche from January 2018 to May 2021. Prior to that, Mr. Lundgren served in roles of increasing responsibility at Genentech from May 2007 to December 2017, including serving as Senior Marketing Director supporting the launch and commercialization of Ocrevus® (ocrelizumab). Mr. Lundgren began his career in the consulting industry. Mr. Lundgren earned his Bachelor of Arts in Public Policy from Duke University and his Master of Business Administration from Harvard Business School.
Positions
- Company NameImmunic, Inc.Stock CodeIMUXPositionCEO & DirectorColleagues
- JTJason TardioCOO & President
- MWMichael Weston BonneyChair of the Board
- GWGlenn WhaleyChief Financial Officer
- HKHella KohlhofCo-Founder & Chief Scientific Officer
- JBJessica BreuVice President of Investor Relations & Communications
- JNJorg NeermannIndependent Director
- BABarclay A. PhillipsLead Independent Director
- JCJon CongletonIndependent Director
